| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Reinis Svarcbahs, Ulrika H Julku, Susanna Norrbacka, Timo T Myöhäne. Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo. Scientific reports. vol 8. issue 1. 2018-12-11. PMID:29367610. |
animal behavior was studied by locomotor activity and cylinder tests, microdialysis and hplc were used to analyze dopamine levels, and different asyn forms and loss of dopaminergic neurons were studied by immunostainings. |
2018-12-11 |
2023-08-13 |
mouse |
| Elke Edelmann, Volkmar Lessman. Dopaminergic innervation and modulation of hippocampal networks. Cell and tissue research. vol 373. issue 3. 2018-12-11. PMID:29470647. |
while the role and importance of dopaminergic modulation of hippocampal networks have been unequivocally proven, there is still a lack of detailed molecular and cellular mechanistic understanding of how dopamine orchestrates these hippocampal processes. |
2018-12-11 |
2023-08-13 |
Not clear |
| Nicole D Harriott, John P Williams, Evan B Smith, Haig P Bozigian, Dimitri E Grigoriadi. VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Progress in medicinal chemistry. vol 57. issue 1. 2018-12-11. PMID:29680151. |
drugs that modify the dopaminergic system by modulating the activity of dopamine have been successful in demonstrating clinical efficacy by providing treatments for these diseases. |
2018-12-11 |
2023-08-13 |
Not clear |
| Daniela Molina-Mateo, Nicolás Fuenzalida-Uribe, Sergio Hidalgo, Claudia Molina-Fernández, Jorge Abarca, Rafaella V Zárate, Marcela Escandón, Reinaldo Figueroa, María Florencia Tevy, Jorge M Campusan. Characterization of a presymptomatic stage in a Drosophila Parkinson's disease model: Unveiling dopaminergic compensatory mechanisms. Biochimica et biophysica acta. Molecular basis of disease. vol 1863. issue 11. 2018-11-26. PMID:28716706. |
these compensatory changes are associated to specific components of the dopaminergic system: the biosynthetic enzymes, tyrosine hydroxylase and dopa decarboxylase, and the dopamine transporter, a plasma membrane protein involved in maintaining dopamine extracellular levels at physiologically relevant levels. |
2018-11-26 |
2023-08-13 |
drosophila_melanogaster |
| J P Kesby, D W Eyles, J J McGrath, J G Scot. Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Translational psychiatry. vol 8. issue 1. 2018-11-26. PMID:29382821. |
our contemporary knowledge regarding dopamine dysfunction has clarified where and when dopaminergic alterations may present in schizophrenia. |
2018-11-26 |
2023-08-13 |
human |
| Meng-Yang Zh. Noradrenergic Modulation on Dopaminergic Neurons. Neurotoxicity research. vol 34. issue 4. 2018-11-26. PMID:29572781. |
it is now well accepted that there is a close relationship between noradrenergic and dopaminergic neurons in the brain, especially referring to the modulation of the locus coeruleus-norepinephrine (lc-ne) system on dopamine transmission. |
2018-11-26 |
2023-08-13 |
Not clear |
| Vívian T da Silveira, Jivago Röpke, Ana L Matosinhos, Ana C Issy, Elaine A Del Bel, Antônio C de Oliveira, Fabrício A Moreir. Effects of the monoamine stabilizer (-)-OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity. Naunyn-Schmiedeberg's archives of pharmacology. vol 391. issue 7. 2018-11-26. PMID:29691608. |
the dopamine stabilizer (-)-osu6162 prevents the hyperactivity induced by dopaminergic and anti-glutamatergic drugs at doses that preserve motor functions, although it failed in the ppi test. |
2018-11-26 |
2023-08-13 |
mouse |
| P R A Heckman, A Blokland, N P Van Goethem, B T J Van Hagen, J Prickaert. The mediating role of phosphodiesterase type 4 in the dopaminergic modulation of motor impulsivity. Behavioural brain research. vol 350. 2018-11-26. PMID:29778625. |
as a result, we investigated the effects of intracellular modulation of the dopamine cascade by means of pde4 inhibition by roflumilast on premature responding in a hypo, normal and hyper dopaminergic state of the brain. |
2018-11-26 |
2023-08-13 |
rat |
| T Mann, K Zilles, H Dikow, A Hellfritsch, M Cremer, M Piel, F Rösch, A Hawlitschka, O Schmitt, A Wre. Dopamine, Noradrenaline and Serotonin Receptor Densities in the Striatum of Hemiparkinsonian Rats following Botulinum Neurotoxin-A Injection. Neuroscience. vol 374. 2018-11-20. PMID:29421436. |
parkinson's disease (pd) is characterized by a degeneration of dopaminergic neurons in the substantia nigra pars compacta (snpc) that causes a dopamine (da) deficit in the caudate-putamen (cpu) accompanied by compensatory changes in other neurotransmitter systems. |
2018-11-20 |
2023-08-13 |
rat |
| Yi-Ting Wang, Hui-Ching Lin, Wei-Zhong Zhao, Hui-Ju Huang, Yu-Li Lo, Hsiang-Tsui Wang, Anya Maan-Yuh Li. Acrolein acts as a neurotoxin in the nigrostriatal dopaminergic system of rat: involvement of α-synuclein aggregation and programmed cell death. Scientific reports. vol 7. 2018-11-16. PMID:28401906. |
acrolein-induced neurodegeneration of nigrostriatal dopaminergic system was delineated by reductions in tyrosine hydroxylase (th) levels, dopamine transporter levels and th-positive neurons in the infused sn as well as in striatal dopamine content. |
2018-11-16 |
2023-08-13 |
rat |
| Marie A Labouesse, Andrea M Sartori, Oliver Weinmann, Eleanor H Simpson, Christoph Kellendonk, Ulrike Weber-Stadlbaue. Striatal dopamine 2 receptor upregulation during development predisposes to diet-induced obesity by reducing energy output in mice. Proceedings of the National Academy of Sciences of the United States of America. vol 115. issue 41. 2018-11-15. PMID:30254156. |
dopaminergic signaling in the striatum, particularly at dopamine 2 receptors (d2r), has been a topic of active investigation in obesity research in the past decades. |
2018-11-15 |
2023-08-13 |
mouse |
| Rodrigo N Ferreira, Aline S de Miranda, Natalia P Rocha, Ana C Simoes E Silva, Antonio L Teixeira, Elizabeth R da Silva Camargo. Neurotrophic Factors in Parkinson's Disease: What Have we Learned from Pre-Clinical and Clinical Studies? Current medicinal chemistry. vol 25. issue 31. 2018-11-14. PMID:29532753. |
these neurological alterations are probably due to the death of dopaminergic neurons in the substantia nigra pars compacta and consequent reduction of dopamine input into the striatum. |
2018-11-14 |
2023-08-13 |
Not clear |
| Won-Seok Choi, Hyung-Wook Kim, François Tronche, Richard D Palmiter, Daniel R Storm, Zhengui Xi. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons. Scientific reports. vol 7. 2018-11-08. PMID:28327638. |
conditional deletion of ndufs4 in dopaminergic neurons promotes parkinson's disease-like non-motor symptoms without loss of dopamine neurons. |
2018-11-08 |
2023-08-13 |
mouse |
| Won-Seok Choi, Hyung-Wook Kim, François Tronche, Richard D Palmiter, Daniel R Storm, Zhengui Xi. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons. Scientific reports. vol 7. 2018-11-08. PMID:28327638. |
this conditional deletion of ndufs4, which reduces complex i activity in dopamine neurons, did not cause a significant loss of dopaminergic neurons in substantia nigra pars compacta (snpc), and there was no loss of dopaminergic neurites in striatum or amygdala. |
2018-11-08 |
2023-08-13 |
mouse |
| Won-Seok Choi, Hyung-Wook Kim, François Tronche, Richard D Palmiter, Daniel R Storm, Zhengui Xi. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons. Scientific reports. vol 7. 2018-11-08. PMID:28327638. |
these data suggest that mitochondrial complex i dysfunction in dopaminergic neurons promotes non-motor symptoms of parkinson's disease and reduces dopamine content in the absence of dopamine neuron loss. |
2018-11-08 |
2023-08-13 |
mouse |
| Javier Castro-Hernández, Paul A Adlard, David I Finkelstei. Pramipexole restores depressed transmission in the ventral hippocampus following MPTP-lesion. Scientific reports. vol 7. 2018-11-06. PMID:28290500. |
to date, however, few studies have investigated dopaminergic innervation in the hippocampus or the functional consequences of reduced dopamine in disease models. |
2018-11-06 |
2023-08-13 |
Not clear |
| Javier Castro-Hernández, Paul A Adlard, David I Finkelstei. Pramipexole restores depressed transmission in the ventral hippocampus following MPTP-lesion. Scientific reports. vol 7. 2018-11-06. PMID:28290500. |
in this work we investigated the role of dopamine on hippocampal long term potentiation using d-amphetamine, which stimulates dopamine release, and also examined how a dopaminergic lesion affects the synaptic transmission across the anatomic subdivisions of the hippocampus. |
2018-11-06 |
2023-08-13 |
Not clear |
| Agnieszka Wąsik, Irena Romańska, Agnieszka Zelek-Molik, Irena Nalepa, Lucyna Antkiewicz-Michalu. The Protective Effect of Repeated 1MeTIQ Administration on the Lactacystin-Induced Impairment of Dopamine Release and Decline in TH Level in the Rat Brain. Neurotoxicity research. vol 34. issue 3. 2018-11-06. PMID:30129004. |
the results obtained from the in vivo microdialysis study as well as from the ex vivo experiments suggest that multiple administration of 1metiq protects dopaminergic neurons against the lactacystin-induced decline in th concentration in the substantia nigra and prevents disturbances of dopamine release in the striatum. |
2018-11-06 |
2023-08-13 |
rat |
| Fábio G Teixeira, Miguel F Gago, Paulo Marques, Pedro Silva Moreira, Ricardo Magalhães, Nuno Sousa, António J Salgad. Safinamide: a new hope for Parkinson's disease? Drug discovery today. vol 23. issue 3. 2018-11-05. PMID:29339106. |
the loss of dopaminergic neurons (dan) and reduced dopamine (da) production underlies the reasoning behind the gold standard treatment for parkinson's disease (pd) using levodopa (l-dopa). |
2018-11-05 |
2023-08-13 |
Not clear |
| Katelyn H Struntz, Jessica A Siege. Effects of methamphetamine exposure on anxiety-like behavior in the open field test, corticosterone, and hippocampal tyrosine hydroxylase in adolescent and adult mice. Behavioural brain research. vol 348. 2018-11-05. PMID:29680785. |
tyrosine hydroxylase is the rate limiting enzyme in the synthesis of dopamine and was used as a marker of the hippocampal dopaminergic system. |
2018-11-05 |
2023-08-13 |
mouse |